When families ask about memantine vs donepezil for a loved one newly diagnosed with Alzheimer’s, they usually want a simple answer. Which one is better? The honest reply is that these drugs aren’t really competitors. They work on completely different parts of brain chemistry, and for many patients, the real question isn’t which drug, but when to start each one.
Both are FDA-approved. Both have been used for decades. Neither reverses Alzheimer’s or stops it in its tracks. What they can do, for a meaningful subset of patients, is soften symptoms and buy time.
Here’s what the evidence actually says, and how clinicians think through the choice in practice.
How Memantine and Donepezil Actually Work
Donepezil (brand name Aricept) is a cholinesterase inhibitor. It blocks the enzyme that breaks down acetylcholine, a neurotransmitter involved in memory and learning. In Alzheimer’s, acetylcholine-producing neurons die off early, so keeping the remaining supply around longer can help cognition. The FDA approved donepezil for all stages of Alzheimer’s disease, from mild to severe.
Memantine (brand name Namenda) works differently. It’s an NMDA receptor antagonist, which means it dampens overactive glutamate signaling in the brain. Too much glutamate is thought to damage neurons in Alzheimer’s, and memantine acts like a shock absorber. According to the National Institute on Aging, it’s approved for moderate to severe Alzheimer’s, not mild disease.
So already we have a clue about the memantine vs donepezil question. They’re approved for overlapping but not identical stages.
Memantine vs Donepezil: What the Studies Show
Head-to-head comparisons are actually pretty limited. Most trials compared each drug to placebo, not to each other.
What we do know:
- Donepezil shows modest cognitive benefit in mild, moderate, and severe Alzheimer’s. Improvements on cognitive scales are real but small, and most patients still decline over time (just a bit more slowly).
- Memantine shows benefit mainly in moderate to severe disease. In mild Alzheimer’s, the evidence is weak, and it’s generally not recommended as monotherapy.
- Combination therapy (both drugs together) shows better outcomes than either alone in moderate to severe stages, per multiple Cochrane reviews and a widely-cited JAMA analysis.
What I tell families is this. If your loved one is in the mild stage, donepezil is usually first. If they’re already in moderate or severe territory, many clinicians will add memantine on top of donepezil rather than switch. The two drugs don’t cancel each other out because they target different pathways.
Side Effects: Where They Really Differ
This is where the memantine vs donepezil comparison gets practical. Because families deal with side effects daily.
Donepezil side effects tend to be cholinergic, meaning too much acetylcholine activity elsewhere in the body:
- Nausea, diarrhea, loss of appetite
- Vivid dreams or nightmares (a common complaint)
- Slow heart rate, sometimes fainting
- Muscle cramps
- Weight loss
Roughly one in five patients has GI issues in the first few weeks. Some settle in. Others don’t tolerate it at all. We wrote more about the warning signs to watch for with donepezil if you want a deeper look.
Memantine side effects are usually milder and different in flavor:
- Dizziness
- Headache
- Confusion (ironic, given the indication)
- Constipation
Memantine is generally better tolerated. That’s probably the single biggest practical advantage it has. If a patient can’t handle donepezil’s GI effects, memantine becomes attractive earlier, even off the strict staging guidelines.
For patients considering other cholinesterase inhibitors instead of donepezil, our comparison of rivastigmine and donepezil covers the trade-offs, and the rivastigmine patch versus pill discussion is worth reading if stomach issues are the main hurdle.
Dosing and Practical Considerations
Both drugs are typically started low and titrated up. Your prescriber will determine the right dose, but here’s the general shape:
Donepezil starts at 5 mg once daily, usually at bedtime, and may increase to 10 mg or 23 mg over weeks. The higher dose has more side effects with only modest additional benefit, so many clinicians stay at 10 mg.
Memantine starts at 5 mg daily and titrates up by 5 mg weekly to a target of 10 mg twice daily (or 28 mg once daily for the extended-release form). Slower titration reduces the confusion and dizziness that can crop up early.
Both drugs are available as generics, which matters. Brand-name Aricept and Namenda can run several hundred dollars a month. Generic donepezil and memantine are typically under $20 a month at most US pharmacies. Compare pricing on generic Alzheimer’s medications at edrugstore.com if cost is a factor.
When to Choose Which, and When to Combine
Here’s how the decision typically plays out:
- Mild Alzheimer’s: Start with donepezil (or another cholinesterase inhibitor like galantamine or rivastigmine). Memantine isn’t first-line here.
- Moderate Alzheimer’s: Donepezil remains standard. Adding memantine is reasonable, especially if behavioral symptoms are prominent.
- Severe Alzheimer’s: Combination therapy is the norm. Both drugs together outperform either alone on functional and cognitive scales.
- Patient can’t tolerate donepezil: Memantine alone is a reasonable fallback, even in mild-to-moderate disease, based on tolerability.
Also worth mentioning: neither drug treats the underlying pathology. Newer agents like lecanemab target amyloid plaques directly and are a different conversation. The Alzheimer’s Association has a good overview of where each treatment fits.
The Bottom Line
The memantine vs donepezil question doesn’t usually have one winner. Donepezil is the workhorse across all stages, especially mild disease. Memantine shines in moderate to severe Alzheimer’s and is often added rather than substituted. Tolerability, stage of disease, and other medical conditions all shape the right pick.
Talk to your prescriber about which fits your loved one’s situation, and ask a pharmacist to review the full medication list for interactions before starting either drug. Small tweaks in timing or dose can make a meaningful difference in how well these medications are tolerated.
This article is for informational purposes only and is not medical advice. Always consult a licensed pharmacist or physician before starting, stopping, or changing any medication.
References
- FDA Drug Information, official approval status and labeling for donepezil and memantine.
- National Institute on Aging, overview of approved Alzheimer’s treatments by disease stage.
- JAMA Network, peer-reviewed analyses of combination therapy outcomes.
- Alzheimer’s Association, patient-facing guide to Alzheimer’s medications and staging.
Dr Steven Schlosser
Dr. Schlosser graduated from Lafayette College Phi Beta Kappa and attended Georgetown Medical School. He had 4 years of medical residency training at Tufts University in Boston in both Gynecology and Internal Medicine. He has had a spotless medical career for the past 40+ years and is Board Certified. Learn More